natgillin/translations-raw huggingface dataset:
indigestion or heartburn
probavne tegobe ili žgaravica
indigestion or heartburn (dyspepsia) diarrhoea.
probavne smetnje ili žgaravica (dispepsija)
indigestion or stomach upset
probavne tegobe ili nadražen želudac
indigestion,
loša probava,
indigestion,
probavne smetnje,
indigestion,
probavne tegobe
Indigestion, abdominal discomfort
loša probava, nelagoda u trbuhu
indigestion, bloating
probavne tegobe, nadutost
indigestion, bloating, flatulence
probavne smetnje, nadutost, vjetrovi
Indigestion, dry mouth
probavne tegobe, suha usta
indigestion, feeling or being sick to your stomach
probavne tegobe, mučnina ili povraćanje
Indigestion, feeling sick (nausea), being sick (vomiting), dry mouth.
probavne tegobe, mučnina, povraćanje, suha usta
indigestion, flatulence
probavne smetnje, vjetrovi
Indigestion, heartburn
probavne tegobe, žgaravica
indigestion, stomach ache or sore mouth
probavne tegobe, bol u trbuhu ili bol u ustima
Indigestion, stomach problems, heartburn, feeling bloated, passing wind, dry mouth
Probavne tegobe, problemi sa želucem, žgaravica, osjećaj nadutosti, vjetrovi, suha usta
indigestion, taste disturbance
probavne tegobe, poremećaj okusa
indigestion, taste disturbance
probavne tegobe, smetnje vezane za okus
Indigestion.
loša probava
Indigestion.
probavne tegobe.
indigestion; constipation
probavne tegobe; zatvor
Indigo carmine (E 132) aluminium lake
celuloza, mikrokristalična indigo carmine (E 132) aluminium lake
Indigo carmine (E132) aluminium lake
propilenglikol indigo carmine (E132) aluminium lake
Indigo carmine (E132) Titanium dioxide (E171) Gelatin
Kapica indigo karmin (E132) titanijev dioksid (E171) želatina
Indigo carmine (E132), lake Yellow iron oxide (E172) Titanium dioxide (E171) Gelatine
indigo karmin (E132), lake žuti željezov oksid (E172) titanijev dioksid (E171) želatina
Indigo carmine aluminium lake (E 132)
Boja Indigo carmine aluminium lake (E 132)
Indigo carmine aluminium lake (E132)
ojin lecitin boja Indigo carmine aluminium lake (E132)
Indigo carmine aluminium lake (E132)
talk boja indigo carmine aluminium lake (E132)
Indigo carmine aluminium lake (E132)
talk indigo carmine aluminium lake (E132)
Indigo carmine aluminium lake (E132) Brilliant blue FCF aluminium lake (E133) Iron oxide black (E172)
Indigo karmin aluminija jezera (E132) Brilliant Blue FCF aluminija jezera (E133) Željezni oksid crni (E172)
Indigo carmine aluminium lake (E132) Carnauba wax
Boja indigo carmine aluminium lake (E132) Karnauba vosak
Indigo Carmine Aluminium Lake E 132 Hypromellose
laktoza hidrat krosprovidon vrste A indigo carmine aluminium lake E 132 hipromeloza
Indigo Carmine Aluminium Lake E132 Triacetin
Indigo carmine aluminium lake (E132) triacetin
Indigo carmine aluminium lake Lactose monohydrate Polyethylene glycol
boja indigo carmine aluminium lake
Indinavir
20,84)
indinavir (0.33 mg/l) when given with ritonavir and efavirenz was higher than the mean historical Cmin (0.15 mg/l) when indinavir was given alone at 800 mg q8h.
Geometrijska srednja vrijednost Cmin indinavira (0,33 mg/l) kad se davao s ritonavirom i efavirenzom bila je viša od povijesne srednje vrijednosti Cmin (0,15 mg/l) kad se indinavir davao sam u dozi od 800 mg svakih 8h.
Indinavir (800 mg TID) [CYP3A4 inhibitor and substrate]
pseudomembransk i kolitis
Indinavir (CYP3A4/5 strong inhibitor and substrate)
Indinavir (jaki inhibitor i supstrat za CYP3A4/5)
Indinavir (CYP3A4/5 strong inhibitor and substrate)
Indinavir (snaţan inhibitor i supstrat za CYP3A4/5)
indinavir 1,000 mg q8h was given
1000 mg svakih 8h primjenjivao s
Indinavir and
Indinavir i
Indinavir and didanosine
3 sata nakon indinavira.
Indinavir and fluconazole can be co-administered without dose adjustment.
istodobno primjenjivati bez prilagođavanja doze.
Indinavir and isoniazid can be co-administered without dose adjustment.
istodobno primjenjivati bez
Indinavir and methadone
Indinavir i metadon mogu se
Indinavir and norethindrone/ethinyl estradiol 1/35 can be co- administered without dose adjustment.
Indinavir i noretindron/etinilestradiol 1/35 mogu se primijeniti istodobno bez prilagođavanja doze.
Indinavir at concentrations of 25 to 100 nM mediated 95 % inhibition of viral spread in cultures of mitogen–activated human peripheral blood mononuclear cells infected with diverse, primary clinical isolates of HIV1, including isolates resistant to zidovudine and non– nucleoside reverse transcriptase inhibitors (NNRTIs).
Indinavir je pri koncentracijama od 25 do 100 nM doveo do 95%-tne inhibicije širenja virusa u kulturama mitogenom aktiviranih mononuklearnih stanica iz ljudske periferne krvi, zaraženih različitim, prvenstveno kliničkim izolatima HIV1, uključujući izolate rezistentne na zidovudin i nenukleozidne inhibitore reverzne transkriptaze.
Indinavir at concentrations of 50 to 100 nM mediated 95 % inhibition (IC95) of viral spread (relative to an untreated virus–infected control) in human T–lymphoid cell cultures and primary human monocytes/macrophages infected with HIV1 variants LAI, MN, RF, and a macrophage–tropic variant SF–162, respectively.
Indinavir je pri koncentracijama od 50 do 100 nM doveo do 95%-tne inhibicije (IC95) širenja virusa (u usporedbi s neliječenom skupinom zaraženom virusom) u kulturama humanih T–limfoidnih stanica i primarnim humanim monocitima/makrofagima zaraženim varijantama HIV1: LAI, MN, RF odnosno makrofagotropnom varijantom SF-162.
Indinavir AUC and Cmin: ↔
AUC i Cmin indinavira: ↔
Indinavir AUC and Cmin: 
AUC i Cmin indinavira: 
Indinavir AUC ↓ 34 %
AUC indinavira ↓ 34
Indinavir AUC ↓ 56 %
AUC indinavira ↓ 56
Indinavir AUC24hr: 178 %
AUC24hr indinavira: 178
Indinavir AUC24hr:266 %
AUC24h indinavira:266
Indinavir AUC: ↑ 53 %
AUC indinavira: ↑ 53
Indinavir AUC: ↓ 20 %
AUC indinavira: ↓ 20
Indinavir AUC: ↓ 24 %
AUC indinavira: ↓ 24
Indinavir AUC: ↓ 32 %
AUC indinavira: ↓ 32
Indinavir AUC: ↓ 32 %
AUC indinavira: ↓32
Indinavir AUC:  11 % Sildenafil AUC  340 %
AUC indinavira:  11% AUC sildenafila  340
Indinavir AUC:  28 %
AUC indinavira:  28
Indinavir AUC:  31 % Indinavir Cmin:  40 %
AUC indinavira:  31% Cmin indinavira:  40
Indinavir AUC:  46 % Indinavir Cmin:  57 % (Relative to Indinavir 800 mg TID alone)
AUC indinavira:  46% Cmin indinavira:  57% (u odnosu na primjenu samo indinavira u dozi od 800 mg TID)
Indinavir AUC:  54 % Indinavir Cmin: ↓ 81 % (Relative to Indinavir 800 mg TID alone)
AUC indinavira:  54% Cmin indinavira: ↓81% (u odnosu na primjenu samo indinavira u dozi od 800 mg TID)
Indinavir AUC:  92 %
AUC indinavira:  92
Indinavir AUC: 
prilagođavanja doze.
Indinavir AUC: 25 %
AUC indinavira: 25
Indinavir Cmin : ↓ 39 %
Cmin indinavira: ↓ 39
Indinavir Cmin : ↓ 39 %
Cmin indinavira: ↓39
indinavir Cmin ↑ 125% indinavir Cmax ↔
indinavir Cmin ↑ 125
Indinavir Cmin ↑ 298 %
Cmin indinavira ↑ 298
Indinavir Cmin ↓ 27 %
Cmin indinavira ↓ 27
Indinavir Cmin ↓ 50 %
Cmin indinavira ↓ 50
Indinavir Cmin: ↑ 10-fold
AUC24h indinavira: 68% Cmin indinavira: ↑ 10 puta
Indinavir Cmin: ↑ 10-fold
AUC24h indinavira:68% Cmin indinavira: ↑ 10 puta
Indinavir Cmin: ↑ 118 %
Cmin indinavira: ↑ 118
Indinavir Cmin: ↑ 29 %
Cmin indinavira: ↑ 29
Indinavir Cmin: ↑ 49 %
Cmin indinavira: ↑ 49
Indinavir Cmin: ↓ 40 %
Cmin indinavira: ↓ 40
Indinavir Cmin: ↓ 40 %
Cmin indinavira: ↓40
Indinavir Cmin:  57 %
AUC efavirenza: 
Indinavir Cmin:↑ 24-fold
AUC24h indinavira: 220% Cmin indinavira:↑ 24 puta
Indinavir Cmin:↑ 24-fold
AUC24h indinavira:220% Cmin indinavira:↑ 24 puta
Indinavir Cmin:11-fold;
Cmin indinavira:11 puta;
Indinavir did not alter the type, frequency, or severity of known major adverse reactions associated with the use of zidovudine, didanosine, or lamivudine.
Indinavir nije utjecao na vrstu, učestalost ni težinu poznatih glavnih nuspojava povezanih s primjenom zivudina, didanozina ili lamivudina.
Indinavir inhibits CYP3A4 and as a result is
Indinavir inhibira CYP3A4 pa se očekuje
Indinavir inhibits CYP3A4 and as a result is expected to increase the plasma concentrations of these anticonvulsants.
Indinavir inhibira CYP3A4 pa se očekuje
indinavir is contraindicated.
kontraindicirana.
Indinavir is rapidly absorbed in the fasted state with a time to peak plasma concentration of 0.8 hours
Indinavir se natašte brzo apsorbira pa vrijeme postizanja vršne koncentracije u plazmi iznosi 0,8 sati
Indinavir levels may increase on stopping St. John’s wort, and the dose of CRIXIVAN may need adjusting.
Nakon prekida primjene gospine trave može doći do povišenja koncentracije indinavira pa će možda biti potrebno prilagoditi dozu lijeka CRIXIVAN.
indinavir or indinavir/ritonavir.
indinavirom ili indinavirom/ritonavirom.
indinavir or indinavir/ritonavir.
Znatno snižena izloženost lopinaviru.
indinavir plasma concentrations.
indinavira u plazmi.
Indinavir was not highly bound to human plasma proteins (39 % unbound).
Indinavir se nije vezao za humane proteine u plazmi u visokom postotku (39% nevezanog indinavira).
Indinavir was rapidly eliminated with a half–life of 1.8 hours.
Indinavir se eliminirao brzo, uz poluvijek od 1,8 sati.
Indinavir with or without ritonavir should not be administered concurrently with medicinal products with narrow therapeutic windows and which are substrates of CYP3A4.
Indinavir se u kombinaciji s ritonavirom ili bez njega ne smije primjenjivati istodobno s lijekovima koji imaju uzak terapijski raspon i koji su supstrati CYP3A4.
indinavir, lopinavir/ritonavir, saquinavir, tipranavir,
indinavir, lopinavir/ritonavir, sakvinavir, tipranavir
indinavir, nelfinavir, ritonavir, saquinavir: medicines to treat HIV infection.
indinavir, nelfinavir, ritonavir, sakvinavir: lijekovi za liječenje HIV infekcija.
indinavir/ritonavir 800/100 mg twice daily
800/100 mg dva puta na dan vs.
indinavir/ritonavir when given
indinavira/ritonavira kod
indinavir/ritonavir with
indinavira/ritonavira s
indinavir/ritonavir.
nuspojava.
Indinavir/ritonavir/Efavirenz (800 mg twice daily/100 mg twice daily/600 mg once daily)
ritonavir/efavirenz (500 mg dvaput na dan/600 mg jedanput na dan)
Indinavir/Tenofovir disoproxil fumarate (800 mg q8h/300 mg q.d.)
indinavir/tenofovirdizoproksil fumarat (800 mg q8h/300 mg q.d.)
Indinavir: careful monitoring for any occurrence of lack of anti- viral efficacy, and dose increase if required.
Indinavir: paţljivo praćenje radi mogućeg izostanka djelotvornosti i po potrebi povećanje doze.
Indinavir: careful monitoring for any occurrence of lack of anti- viral efficacy, and dose increase if required.
Indinavir: paţljivo praćenje radi mogućeg izostanka djelovanja i po potrebi povećanje doze.
Indinavir: comparison of
Indinavir: usporedba indinavir/ritonavir
Individual
Kod prilagodbe doze
Individual benefit/risk justification
Opravdanost primjene na osnovi individualne procjene koristi/rizika
Individual benefit/risk justification
Procjena omjera koristi/rizika kod pojedinog bolesnika
Individual components of composites
Pojedinačne komponente kompozitnih ishoda
Individual components of Primary Response at Week 32
Pojedinačne komponente primarnog odgovora u 32. tjednu
Individual components of the primary composite endpoint
Pojedinačne komponente primarnog kompozitnog ishoda
Individual disease parameters of spleen volume, liver volume, haemoglobin levels and platelet count remained stable through 24 months.
Pojedinačni parametri bolesti: volumen slezene, volumen jetre, razina hemoglobina i broj trombocita ostali su stabilni tijekom 24 mjeseca.
individual dose ranging
pojedinačna doza u
Individual metals*  10 ppm each
Pojedinačni metali*  10 ppm za svaki
Individual patient dosimetry results were not predictive for [90Y]- radiolabelled Zevalin toxicity.
Iz dozimetrijskih rezultata pojedinačnih bolesnika nije se mogla predvidjeti toksičnost Zevalina radioaktivno označenog izotopom [90Y].
Individual patients may
Pojedinim bolesnicima može
Individual patients may vary in their response to factor IX, achieving different levels of in vivo recovery and demonstrating different half-lives.
Pojedini pacijenti mogu različito odgovarati na faktor IX, postizanjem različitih razina in vivo oporavka te pokazujući različite poluvijekove.
Individual patients may vary in their response to factor IX, demonstrating different half-lives and recoveries.
Pojedini bolesnici mogu se razlikovati u odgovoru na faktor IX demonstrirajući različite poluvijekove i povrate.
Individual patients may vary in their response to factor VIII, achieving different levels of in vivo recovery and demonstrating different half-lives.
Pojedini bolesnici mogu imati različite odgovore na faktor VIII, pri čemu se postižu različite razine povrata in vivo uz različite poluvijekove.
Individual patients may vary in their response to factor VIII, demonstrating different half-lives and recoveries.
Moguće su razlike u odgovoru pojedinačnih bolesnika na faktor VIII u smislu razlika u poluživotu lijeka te trajanju oporavka.
Individual patients may vary in their response to FVIII, achieving different levels of in vivo recovery and demonstrating different half-lives.
Pojedini bolesnici mogu se razlikovati u svojim odgovorima na FVIII i postizati različite razine in vivo povrata i iskazivati različite vrijednosti poluvijeka.
Individual patients may vary in their response to FVIII, achieving different levels of in vivo recovery and demonstrating different half-lives.
Pojedini bolesnici mogu se razlikovati u svojim odgovorima na FVIII i postizati različite razine in vivo povrata te pokazivati različite vrijednosti poluvijeka.
Individual patients’ plasma aztreonam concentrations exhibited considerable variability.
Koncentracije aztreonama u plazmi pojedinih bolesnika pokazale su znatnu varijabilnost.
Individual patients’ sputum aztreonam concentrations exhibited considerable variability.
Koncentracije aztreonama u iskašljaju pojedinih bolesnika pokazale su znatnu varijabilnost.
Individual serotypes for which statistical significance was reached in the effectiveness analysis controlling for confounding factors (no adjustment for multiplicity performed).
Pojedinačni serotipovi za koje je postignuta statistička značajnost u analizi učinkovitosti koja kontrolira zbunjujuće čimbenike (nije provedena prilagodba za umnoženost).
Individual tablets in intact packaging should be separated from the blister using the perforation, e.g. for use in multi-compartment compliance aids.
Pojedinačne tablete u neotvorenom pakiranju trebalo bi odvajati od blistera korištenjem performacije, npr. za upotrebu u organizatorima za lijekove s pretincima.
Individual tolerability and
obzir podnošljivost i virološki
Individual variation in Cmax and t1/2 was observed.
Primjećena je individualna varijacija Cmax i t1/2 .
Individualised dose titration
Individualizirana titracija doze
Individualised prophylaxis: In paediatric subjects on individualised prophylaxis regimen, the median dose interval was 3.49 (interquartile range 3.46-3.51) days and the median total weekly dose was 91.63 (interquartile range 84.72-104.56) IU/kg for subjects <6 years of age and 86.88 (interquartile range 79.12- 103.08) IU/kg for subjects 6 to <12 years of age.
Individualizirana profilaksa: U pedijatrijskih ispitanika koji su primali režim individualizirane profilakse medijan intervala doziranja iznosio je 3,49 (interkvartilni raspon: 3,46-3,51) dana, a medijan ukupne tjedne doze iznosio je 91,63 (interkvartilni raspon: 84,72-104,56) IU/kg za ispitanike u dobi od <6 godina i 86,88 (interkvartilni raspon: 79,12-103,08) IU/kg za ispitanike u dobi od 6 do <12 godina.
Individuals 12 months of age and older
Osobe u dobi od 12 mjeseci i starije
Individuals 12 months of age and older:
Osobama u dobi od 12 mjeseci i starijima:
Individuals 14 years of age and older
Pojedinci u dobi od 14 godina i stariji
Individuals 15 years of age and older at time of first injection
Pojedinci u dobi od 15 godina i stariji u vrijeme prve injekcije
Individuals 60 years of age and over: 0.1 ml.
Osobe u dobi od 60 godina i starije: 0,1 ml.
Individuals 9 to and including 13 years of age
Pojedinci u dobi od 9 do uključujući i 13 godina
Individuals 9 to and including 14 years of age at time of first injection
Pojedinci u dobi od 9 do uključujući i 14 godina u vrijeme prve injekcije
Individuals between 9 and 12 months of age
Osobe u dobi između 9 i 12 mjeseci
Individuals considered to be at a higher risk of pneumococcal infection (such as those with sickle cell disease or HIV infection), including those previously vaccinated with the 23-valent pneumococcal polysaccharide vaccine, may receive at least one dose of Prevenar 13.
Pojedinci koji mogu biti pod povećanim rizikom od pneumokokne infekcije (poput onih s bolesti srpastih stanica ili infekcije HIV-om), uključujući one koji su prethodno cijepljeni s 23-valentnim polisaharidnim cjepivom protiv pneumokoka, mogu primiti barem jednu dozu cjepiva Prevenar 13.
Individuals from birth through 15 years of age: 1 dose (0.5 ml) at each injection:
Osobe u dobi od rođenja do 15 godina: 1 doza (0,5 ml) kod svake injekcije.
Individuals less than 9 months of age
Osobe mlađe od 9 mjeseci
Individuals likely to be susceptible to mumps and rubella
Osobe koje su vjerojatno podložne infekciji parotitisom i rubelom
Individuals may have larger increases than reflected by the mean changes.
U pojedinih osoba povišenja mogu biti veća nego što to pokazuju srednje vrijednosti promjena.
Individuals over the age of 65 years are more likely to have decreased renal function, therefore caution should be exercised when administering Emtricitabine/Tenofovir disoproxil Zentiva to older people.
Kod osoba starijih od 65 godina postoji veća vjerojatnost da imaju smanjenu funkciju bubrega, pa je stoga potreban oprez kada se Emtricitabine/Tenofovir disoproxil Zentiva daje starijim osobama.
Individuals receiving filgrastim who report left upper abdominal and/ or shoulder tip pain should be evaluated for an enlarged spleen or splenic rupture.
Pojedince koji primaju filgrastim i tuže se na bol u lijevom gornjem dijelu abdomena i/ili u vrhu ramena treba pregledati zbog mogućeg povećanja slezene ili rupture slezene.
Individuals receiving filgrastim who report left upper abdominal and/ or shoulder tip pain should be evaluated for an enlarged spleen or splenic rupture.
Pojedince koji primaju filgrastim i žale se na bol u gornjem lijevom dijelu abdomena i/ili bol u vrhu lijevog ramena treba pregledati zbog mogućeg povećanja slezene ili rupture slezene.
Individuals receiving filgrastim who report left upper abdominal and/ or shoulder tip pain should be evaluated for an enlarged spleen or splenic rupture.
U bolesnika koji primaju filgrastim te prijave bolove u lijevom gornjem dijelu abdomena i/ili u vrhu ramena, potrebno je ocijeniti imaju li povećanu slezenu ili rupturu slezene.
Individuals receiving filgrastim who report left upper abdominal and/ or shoulder tip pain should therefore be evaluated for an enlarged spleen or splenic rupture.
Pojedince koji primaju filgrastim i tuže se na bol u lijevom gornjem dijelu abdomena i/ili u vrhu ramena treba pregledati zbog mogućeg povećanja slezene ili rupture slezene.
Individuals receiving filgrastim who report left upper abdominal and/ or shoulder tip pain should therefore be evaluated for an enlarged spleen or splenic rupture.
Pojedince koji primaju filgrastim i žale se na bol u gornjem lijevom dijelu abdomena i/ili bol u vrhu lijevog ramena treba pregledati zbog mogućeg povećanja slezene ili rupture slezene.
Individuals receiving filgrastim who report left upper abdominal and/ or shoulder tip pain should therefore be evaluated for an enlarged spleen or splenic rupture.
U bolesnika koji primaju filgrastim te prijave bolove u lijevom gornjem dijelu abdomena i/ili u vrhu ramena, potrebno je ocijeniti imaju li povećanu slezenu ili rupturu slezene.
Individuals receiving filgrastim who report left upper abdominal and/or shoulder tip pain should be evaluated for an enlarged spleen or splenic rupture.
Pojedince koji primaju filgrastim i tuže se na bol u lijevom gornjem dijelu abdomena i/ili u vrhu ramena treba pregledati zbog mogućeg povećanja slezene ili rupture slezene.
Individuals taking Truvada to prevent HIV-1 infection should be tested at least every 3 months to make sure that they are free of HIV-1.
Osobe koje uzimaju lijek Truvada radi sprečavanja infekcije virusom HIV-1 moraju se barem svaka tri mjeseca podvrgnuti testiranju radi potvrde da nisu zaražene virusom HIV-1.
Individuals with a lowered resistance to diseases.
Osobe sa smanjenom otpornošću na bolesti.
Individuals with complement deficiencies and individuals with functional or anatomical asplenia may not mount an immune response to meningococcal group A, C, W135 and Y conjugate vaccines.
Osobe s deficitom komplementa i one s funkcionalnom ili anatomskom asplenijom možda neće postići imunološki odgovor na konjugirana cjepiva protiv meningokoka grupe A, C, W135 i Y.
Individuals with haemophilia B may develop antibodies (inhibitors) against factor IX.
Osobe s hemofilijom B mogu razviti protutijela (inhibitore) protiv faktora IX.
Individuals with haemophilia B who receive factor IX preparations, should be monitored for the development of neutralising antibodies against factor IX (inhibitors) (see Possible side effects).
Pojedince s hemofilijom B koji primaju pripravke faktora IX potrebno je pratiti zbog razvoja neutralizirajućih protutijela protiv faktora IX (inhibitori) (vidjeti Moguće nuspojave).
Individuals with impaired immune responsiveness, whether due to the use of immune-suppressive therapy, a genetic disorder, or other causes, may have reduced antibody response to active immunization.
Osobe s oštećenom sposobnošću imunološkog odgovora bilo zbog uzimanja imunosupresivne terapije, genetskog poremećaja ili drugih uzroka mogu imati smanjen odgovor protutijela na aktivnu imunizaciju.
Individuals with renal impairment: Since tenofovir disoproxil fumarate can cause renal toxicity, close monitoring of renal function is recommended in any individual with renal impairment treated with receiving Truvada (see sections 4.2, 4.4 and 5.2).
Osobe s oštećenjem funkcije bubrega: Tenofovirdizoproksilfumarat može prouzročiti bubrežnu toksičnost, pa se preporučuje pomno praćenje funkcije bubrega u svake osobe s oštećenom funkcijom bubrega koja se liječi primanjem Truvade (vidjeti dio 4.2, 4.4 i 5.2).
Indolent Non Hodgkin Lymphoma including Follicular Lymphoma
Indolentni ne-Hodgkinov limfom, uključujući folikularni limfom
indometacin, ketoprofen for pain or inflammation
indometacin, ketoprofen za bol ili upalu
indomethacin, ketoprofen for pain or inflammation
indometacin, ketoprofen za liječenje boli ili upale
Indoxacarb (mg/kg)
(mg/kg)
Indoxacarb + permethrin
Indoksakarb + permetrin
Indoxacarb, permethrin
Indoksakarb, permetrin
Induce a penile erection
Inducirajte erekciju penisa
Inducers of CYP3A4
Induktori enzima CYP3A4
Inducers of CYP3A4 may increase the metabolism of sirolimus and decrease sirolimus blood levels (e.g., St. John's Wort (Hypericum perforatum), anticonvulsants: carbamazepine, phenobarbital, phenytoin).
Induktori CYP3A4 mogu povećati metabolizam sirolimusa i smanjiti koncentraciju sirolimusa u krvi [npr. gospina trava (Hypericum perforatum), antikonvulzivi: karbamazepin, fenobarbital, fenitoin].
Inducers of CYP3A4 may increase the metabolism of sirolimus and decrease sirolimus blood levels (e.g., St. John's Wort (Hypericum perforatum), anticonvulsants: carbamazepine, phenobarbital, phenytoin).
Induktori enzima CYP3A4 mogu povećati metabolizam sirolimusa i smanjiti koncentraciju sirolimusa u krvi [npr. gospina trava (Hypericum perforatum), antikonvulzivi: karbamazepin, fenobarbital, fenitoin].
Inducers of cytochromes P450: Rifampicin (600 mg daily), a potent inducer of CYP3A and CYP2B6, and an inducer of CYP2C9, CYP2C19, and CYP2C8, did not significantly change the pharmacokinetics of prasugrel.
Induktori citokroma P450: Rifampicin (600 mg na dan), snažan induktor CYP3A i CYP2B6 te induktor CYP2C9, CYP2C19 i CYP2C8, nije značajno promijenio farmakokinetiku prasugrela.
Inducers of P-gp (St. John’s wort, rifampicin) might therefore decrease the bioavailability of aliskiren.
Induktori P-gp-a (Gospina trava, rifampicin) stoga bi mogli smanjiti bioraspoloživost aliskirena.
Inducers of P-gp (St. John’s wort, rifampicin) might therefore decrease the bioavailability of Rasilez.
Induktori P-gp-a (Gospina trava, rifampicin) stoga bi mogli smanjiti bioraspoloživost Rasileza.